MedTrace Logo

Extended Clomiphene Citrate Regimen in Women With Polycystic Ovary Syndrome

NCT02381184 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2016-08-23

No results posted yet for this study

Summary

One hundred and thirty six anovulatory women with CC-resistant PCOS were scheduled randomly into two equal groups. Group A (n=68); received CC (100 mg/day from cycle day 3 for 10 days) for up to six cycles. Group B (n=68) underwent LOD and followed up for 6 months. The primary outcome was the ovulation rate in each group; secondary outcomes were midcycle endometrial thickness and serum estradiol, midluteal serum progesterone, and the rates of clinical pregnancy and abortion.

Conditions

Interventions

DRUG

clomiphene citrate

receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.

PROCEDURE

laparoscopic ovarian drilling (LOD)

Laparoscopy was performed under general anesthesia, using three-puncture technique

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • ahmed morad · assistant professor

  • khalid mohamed · lecturer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381184 on ClinicalTrials.gov